During the past decade, Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer" #1 collaborator was "NordForsk" with 2 trials as a collaborator, "The Swedish Childhood Cancer Foundation" with 2 trials as a collaborator, "Aamu Pediatric Cancer Foundation" with 1 trials as a collaborator, "Acreditar - Associação de Pais e Amigos das Crianças com Cancro" with 1 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer" are "Leukemia, Acute Lymphoblastic" (2 trials), "Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials), "Cancer of Unknown Primary Site" (1 trials) and "DLBCL" (1 trials). Many other conditions were trialed in "Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer" in a lesser frequency.

Most popular intervention types in "Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer" are "Drug" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (2 trials), "Pertuzumab" (2 trials), "5-Fluorouracil" (1 trials), "6-tioguanine+Standard Maintenance Therapy" (1 trials) and "Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma" (1 trials). Other intervention names were less common.

The vast majority of trials in "Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".